|
|
Article: As Antegren Makes Fast Tracks, Elan Bolsters Pain Drug NDA.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
In a move that could markedly quicken the approval pace for its snail-based synthetic pain drug, Prialt, Elan Corp. plc added encouraging Phase III data to the new drug application and expects a review time of about six months.
The news came one day after Dublin, Ireland-based Elan disclosed that its other late-stage product candidate, Antegren (natalizumab), for multiple sclerosis, won fast-track designation from the FDA. Antegren, co-developed with Biogen Idec Inc., of Cambridge, Mass., also targets Crohn's disease.
Elan's stock (NYSE:ELN) closed Tuesday at $24.38, down 2 cents, having jumped 43 cents on Monday's Antegren ...
Related newspaper, magazine, and journal articles:
|